InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
2
Disclosed sells
0
T+90 hit rate
67%
T+90 mean return
-18.6%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Manion Douglas J., Directeur Exécutif. Director active across 2 companies, notably Arena Pharmaceuticals INC. In total, 9 disclosures have been published. Breakdown: 2 buys · 0 sell. Total volume traded: €94k. History available since 15 August 2021. The latest transaction was filed on 17 March 2023 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations9 total
27,000 sharesCommon StockSEC:0001209191-24-000416:0
15,575 sharesCommon StockSEC:0001209191-23-044445:0
6,300 shares@ US$7.862349.5% of flowCommon StockSEC:0001209191-23-019743:0
Ideal exit: 12 Dec 2023 (T+270)
6,500 shares@ US$7.73550.5% of flowCommon StockSEC:0001209191-23-017626:0
Ideal exit: 4 Dec 2023 (T+270)
15,000 sharesCommon StockSEC:0001628280-22-005892:0
21,462 shares0Common StockSEC:0001628280-22-000342:0
21,462 shares0Common StockSEC:0001628280-22-000342
15,000 shares0Common StockSEC:0001628280-21-017169
15,000 shares0Common StockSEC:0001628280-21-017169:0
9 of 9 declarations
About Manion Douglas J.
Douglas J. Manion is the EVP of Research & Development at Arena Pharmaceuticals Inc. He oversees the company's research and development initiatives aimed at innovating in the pharmaceutical field. With deep expertise, Douglas plays a crucial role in the strategy for developing new treatments and products.
